vs

Side-by-side financial comparison of General Enterprise Ventures, Inc. (CITR) and Pelthos Therapeutics Inc. (PTHS). Click either name above to swap in a different company.

Pelthos Therapeutics Inc. is the larger business by last-quarter revenue ($294.0K vs $288.2K, roughly 1.0× General Enterprise Ventures, Inc.). General Enterprise Ventures, Inc. runs the higher net margin — -2751.2% vs -5523.1%, a 2772.0% gap on every dollar of revenue.

The Hewlett Packard Enterprise Company (HPE) is an American multinational information technology company based in Spring, Texas. It is a business-focused organization which works in servers, storage, networking, containerization software and consulting and support. HPE was ranked No. 107 in the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Pelthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare metabolic and endocrine diseases with significant unmet medical needs. It operates primarily across North America and Europe, with a pipeline of novel drug candidates addressing underserved patient populations.

CITR vs PTHS — Head-to-Head

Bigger by revenue
PTHS
PTHS
1.0× larger
PTHS
$294.0K
$288.2K
CITR
Higher net margin
CITR
CITR
2772.0% more per $
CITR
-2751.2%
-5523.1%
PTHS

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
CITR
CITR
PTHS
PTHS
Revenue
$288.2K
$294.0K
Net Profit
$-7.9M
$-16.2M
Gross Margin
-99.7%
-687.8%
Operating Margin
-1470.3%
-5225.2%
Net Margin
-2751.2%
-5523.1%
Revenue YoY
169.3%
Net Profit YoY
-1110.1%
-858.0%
EPS (diluted)
$-0.59
$-5.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CITR
CITR
PTHS
PTHS
Q3 25
$288.2K
$294.0K
Q2 25
$687.6K
Q1 25
$969.4K
Q2 24
$198.7K
Q1 24
$433.0K
Q4 23
$262.0K
Q3 23
$174.7K
Q2 23
$28.4K
Net Profit
CITR
CITR
PTHS
PTHS
Q3 25
$-7.9M
$-16.2M
Q2 25
$-11.9M
Q1 25
$-10.9M
Q2 24
$-907.4K
Q1 24
$-3.5M
Q4 23
$-184.2K
Q3 23
$-9.1M
Q2 23
$-417.9K
Gross Margin
CITR
CITR
PTHS
PTHS
Q3 25
-99.7%
-687.8%
Q2 25
46.0%
Q1 25
42.5%
Q2 24
48.6%
Q1 24
79.2%
Q4 23
71.4%
Q3 23
77.2%
Q2 23
82.7%
Operating Margin
CITR
CITR
PTHS
PTHS
Q3 25
-1470.3%
-5225.2%
Q2 25
-438.8%
Q1 25
-356.8%
Q2 24
-456.7%
Q1 24
-608.9%
Q4 23
-69.6%
Q3 23
-5198.9%
Q2 23
-1471.6%
Net Margin
CITR
CITR
PTHS
PTHS
Q3 25
-2751.2%
-5523.1%
Q2 25
-1731.1%
Q1 25
-1124.8%
Q2 24
-456.7%
Q1 24
-812.8%
Q4 23
-70.3%
Q3 23
-5199.9%
Q2 23
-1473.7%
EPS (diluted)
CITR
CITR
PTHS
PTHS
Q3 25
$-0.59
$-5.30
Q2 25
$-0.19
Q1 25
$-0.23
Q2 24
$-0.02
Q1 24
$-0.04
Q4 23
$-0.01
Q3 23
$-0.09
Q2 23
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CITR
CITR
PTHS
PTHS
Cash + ST InvestmentsLiquidity on hand
$14.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$8.5M
$58.3M
Total Assets
$12.3M
$126.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CITR
CITR
PTHS
PTHS
Q3 25
$14.2M
Q2 25
Q1 25
Q2 24
Q1 24
Q4 23
Q3 23
Q2 23
Stockholders' Equity
CITR
CITR
PTHS
PTHS
Q3 25
$8.5M
$58.3M
Q2 25
$2.2M
Q1 25
$4.1M
Q2 24
$3.2M
Q1 24
$3.8M
Q4 23
Q3 23
$3.3M
Q2 23
$2.8M
Total Assets
CITR
CITR
PTHS
PTHS
Q3 25
$12.3M
$126.4M
Q2 25
$8.7M
Q1 25
$9.1M
Q2 24
$5.4M
Q1 24
$5.3M
Q4 23
$5.3M
Q3 23
$5.3M
Q2 23
$4.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CITR
CITR
PTHS
PTHS
Operating Cash FlowLast quarter
$-1.5M
$-15.3M
Free Cash FlowOCF − Capex
$-1.5M
FCF MarginFCF / Revenue
-525.6%
Capex IntensityCapex / Revenue
18.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CITR
CITR
PTHS
PTHS
Q3 25
$-1.5M
$-15.3M
Q2 25
$-1.2M
Q1 25
$-713.9K
Q2 24
$-424.9K
Q1 24
$-343.7K
Q4 23
$-391.8K
Q3 23
$-396.0K
Q2 23
$-247.0K
Free Cash Flow
CITR
CITR
PTHS
PTHS
Q3 25
$-1.5M
Q2 25
$-1.4M
Q1 25
$-740.9K
Q2 24
Q1 24
Q4 23
Q3 23
$-398.3K
Q2 23
FCF Margin
CITR
CITR
PTHS
PTHS
Q3 25
-525.6%
Q2 25
-196.7%
Q1 25
-76.4%
Q2 24
Q1 24
Q4 23
Q3 23
-228.0%
Q2 23
Capex Intensity
CITR
CITR
PTHS
PTHS
Q3 25
18.7%
Q2 25
20.5%
Q1 25
2.8%
Q2 24
0.0%
Q1 24
0.0%
Q4 23
Q3 23
1.3%
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons